AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Plexus Vaccine Licenses Molsoft To Develop Proprietary Virtual Epitope Databases.
2001 OCT 17 - (NewsRx.com & NewsRx.net) -- Plexus Vaccine Inc. and Molsoft LLC have entered into a key licensing agreement to discover and commercialize new interventional strategies for global infectious diseases, for drug-resistant microbes, and for chronic diseases associated with cryptic pathogens. Using the Molsoft ICM software suite, Plexus is developing Virtual Epitope databases of molecular disease targets for in silico design of structural mimics that can be readily synthesized, tested, and formulated as vaccines.
"This alliance represents an opportunity to use Molsoft's molecular modeling software and Plexus Vaccine's structure-based vaccine design to develop epitope-specific vaccines that generate neutralizing antibodies using deduction and mimicry of the 3D structural features of epitopes," said Dr. Ruben Abagyan, founder of MolSoft. "This approach will hasten the development of safe and effective vaccines." To facilitate maximum communication between Plexus and MolSoft, Dr. Abagyan will join the Plexus Vaccine board of directors and scientific advisory board.
"Recent advances in protein structural prediction, genomics, and bioinformatics have brought new ...
- Plexus Vaccine Inc Forges Licensing Agreement With Molsoft LLC.
- Press release article from: PR Newswire September 11, 2001 700+ words
...Develop Its Proprietary Virtual Epitope(TM) Databases...PRNewswire/ -- Plexus Vaccine Inc, a San Diego...Plexus is developing Virtual Epitope(TM) databases...modeling software and Plexus Vaccine's structure-based...
- Plexus Vaccine Inc Selected to Receive Department of Defense-Funded Competitive...
- Press release article from: PR Newswire February 8, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc, a San Diego biotechnology...amp;D funding that enables Plexus Vaccine to acquire proof of concept for...platform technology. In addition, Plexus Vaccine will receive services, including...
- Plexus Vaccine Inc Appoints Scientific Advisory Board Chaired by Roger Brent Of...
- Press release article from: PR Newswire November 1, 2001 700+ words
...DIEGO, Nov. 1 /PRNewswire/ -- Plexus Vaccine Inc, a San Diego biotechnology company...Board. Supporting Dr. Robert Deans, Plexus Vaccine's VP of Research and Development...role in helping the company employ Plexus Vaccine's Structural Pharmacogenomics technology...
- Plexus Vaccine Inc and GlaxoSmithKline Biologicals Sign Structure-Based...
- Press release article from: PR Newswire July 22, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc announces that it has signed...funded research collaboration, Plexus Vaccine will design chimeric miniproteins...down-stream product rights. "Plexus Vaccine is establishing its leadership...
- Plexus Vaccine Acquires Exclusive Position for Demographically Targeted T-cell...
- Press release article from: PR Newswire June 19, 2002 700+ words
...DIEGO and COPENHAGEN, Denmark -- Plexus Vaccine Inc, a San Diego based biotechnology...Valley centered around Copenhagen. Plexus Vaccine, formed in 2001 and based in San Diego...For additional information about Plexus Vaccine, please visit the Company's web...
- SIGA TECHNOLOGIES, Inc. Announces Intent to Acquire PLEXUS VACCINE Inc. to...
- Press release article from: Business Wire April 1, 2003 700+ words
...letter of intent to acquire substantially all the assets of Plexus Vaccine Inc. The acquisition would expand SIGA's capabilities...developmental timelines". Susan Burgess, President and CEO of Plexus Vaccine, is also optimistic about the competitive strength gained...
- SIGA Technologies, Inc. Signs Definitive Agreement to Acquire Assets of Plexus...
- Press release article from: Business Wire May 15, 2003 700+ words
...acquire substantially all of the assets of San Diego based Plexus Vaccine Inc, including the equity in Plexus's Danish subsidiary...biowarfare defense". Susan Burgess, PhD, President and CEO of Plexus Vaccine will, upon consummation of the acquisition, be named as...
- SIGA EYES PLEXUS TO EXPAND BIOWARFARE DEFENSE RESEARCH.(SIGA Technologies to...
- Magazine article from: BIOWORLD Today Huggett, Brady April 2, 2003 700+ words
Byline: Brady Huggett , Senior Staff Writer SIGA Technologies is planning to buy Plexus Vaccine Inc., looking to expand its vaccine offerings and capitalize on government funding for the development of biowarfare defense...
